High incidence of intolerance to tuberculosis chemoprophylaxis

Rheumatology International

Volumn 32, Issue 1, 2012, Pages 33-37

  Haroon, Muhammad ^a   Martin, Una ^a   Devlin, Joe ^a  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

Anti TNF agents; DMARDs; Hepatotoxicity; Latent tuberculosis; Prophylaxis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; RIFAMPICIN;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; CHEMOPREVENTION; DRUG-INDUCED LIVER INJURY; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; ISONIAZID; LATENT TUBERCULOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RIFAMPIN; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857120107     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1571-6     Document Type: Article

References (20)

1. http://www.isr.ie/-fileupload/File/ISR%20Guidelines%20A4%20(3).pdf
2. British Thoracic Society, Standards of Care Committee 2005 BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment Thorax 60 800 805 10.1136/thx.2005.046797 (Pubitemid 41475202)
3. WM Lee 1995 Drug-induced hepatotoxicity N Engl J Med 333 1118 1127 7565951 10.1056/NEJM199510263331706 1:CAS:528:DyaK28XjvVWl
4. JR Mitchell HJ Zimmerman KG Ishak, et al. 1976 Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis Ann Intern Med 84 181 192 766682 1:STN:280:DyaE287jsVGgsw%3D%3D
5. A Mor CO Bingham 3rd M Kishimoto PM Izmirly JD Greenberg S Reddy PB Rosenthal 2008 Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic Ann Rheum Dis 67 4 462 465 17711866 10.1136/ard.2007.076406 1:CAS:528:DC%2BD1cXltlSlu7c%3D (Pubitemid 351498424)
6. V Strand S Cohen M Schiff A Weaver R Fleischmann G Cannon, et al. 1999 Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group Arch Intern Med 159 2542 2550 10573044 10.1001/archinte.159.21.2542 1:CAS:528:DyaK1MXotVSnurg%3D
7. AM Leak B Rincon-Aznar 2008 Hepatotoxicity associated with etanercept in psoriatic arthritis J Rheumatol 35 11 2286 2287 19004062 10.3899/jrheum.080521
8. AM Garcia Aparicio JR Rey AH Sanz JS Alvarez 2007 Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab Clin Rheumatol 26 5 811 813 16550301 10.1007/s10067-006-0253-y (Pubitemid 46554102)
9. P Brassard AM Lowe S Bernatsky A Kezouh S Suissa 2009 Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada Arthritis Rheum 61 3 300 304 19248128 10.1002/art.24476
10. KG Saag GG Teng NM Patkar J Anuntiyo C Finney JR Curtis, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762 784 18512708 10.1002/art.23721 1:CAS:528: DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
11. Centers for Disease Control and Prevention 2004 Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003 MMWR Morb Mortal Wkly Rep 53 683 686
12. J Keane B Bresnihan 2008 Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies Curr Opin Rheumatol 20 4 443 449 18525359 10.1097/BOR. 0b013e3283025ec2 1:CAS:528:DC%2BD1cXms1yntLg%3D
13. A Raval G Akhavan-Toyserkani A Brinker, et al. 2007 Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab Ann Intern Med 147 699 702 18025446 (Pubitemid 351664465)
14. JJ Gómez-Reino L Carmona M Angel Descalzo Biobadaser Group 2007 Risk of tuberculosis in patients treated with tumour necrosis factor antagonists due to incomplete prevention of reactivation of latent infection Arthritis Rheum 57 5 756 761 17530674 10.1002/art.22768 (Pubitemid 46932080)
15. L Carmona JJ Gómez-Reino V Rodríguez-Valverde, et al. 2005 Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766 1772 15934089 10.1002/art.21043 1:CAS:528:DC%2BD2MXlvFChur0%3D (Pubitemid 40852885)
16. I Sezer H Kocabas MA Melikoglu M Arman 2009 Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy Clin Rheumatol 28 1 53 57 18688673 10.1007/s10067-008-0982-1
17. L Sichletidis L Settas D Spyratos D Chloros D Patakas 2006 Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Int J Tuberc Lung Dis 10 10 1127 1132 17044206 1:STN:280:DC%2BD28nhtFOjsw%3D%3D (Pubitemid 44519351)
18. J Vanhoof S Landewe E Van Wijngaerden P Geusens 2003 High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors Ann Rheum Dis 62 12 1241 1242 14644871 10.1136/ard.2002.004598 1:STN:280:DC%2BD3srpsFGksw%3D%3D (Pubitemid 37500639)
19. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev (2):CD001363
20. Hong Kong Chest Service Tuberculosis Research Centre Madras British Medical Research Council 1992 A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong Am Rev Respir Dis 145 36 41 10.1164/ajrccm/145.1.36